|
| Characteristics | Values |
|
| Age, mean (S.D.) years | 46.2 (13.9) |
| Female sex, n/N () | 100/107 (93.5) |
| Caucasian race, n/N () | 104/107 (97.2) |
| Disease duration, median (range) years | 12 (0-43) |
| Age of SLE onset, mean (S.D.) years | 33.1 (13.3) |
| BMI, median (range) kg/ m2 | 26.5 (17.7-53.5) |
| Current smoker, n/N () | 20/107 (18.7) |
| Current use of sunscreen, n/N () | 46/92 (50) |
| Regular exercise, n/N () | 38/92 (41.3) |
| Family history of SLE in first degree relative, n/N () | 3/92 (3.3) |
| Any co-morbidity, n/N () | 85/107 (79.4) |
| Osteopaenia/osteoporosis, n/N () | 33/107 (30.8) |
| Hypertension, n/N () | 27/107 (25.2) |
| Hypercholesterolaemia on treatment, n/N () | 12/107 (11.2) |
| Diabetes mellitus, n/N () | 9/107 (8.4) |
| Fibromyalgia, n/N () | 10/107 (9.3) |
| Anti-phospholipid syndrome, n/N () | 11/107 (10.3) |
| Sjogren’s syndrome, n/N () | 4/107 (3.7) |
| Rheumatoid arthritis, n/N () | 3/107 (2.8) |
| Current prednisolone, n/N () | 49/107 (45.8) |
| Prednisolone dose, median (range) mg/day | 5.00 (1.25-15.00) |
| Current hydroxychloroquine, n/N () | 65/107 (60.7) |
| Current azathioprine, n/N () | 22/107 (20.6) |
| Current methotrexate, n/N () | 10/107 (9.3) |
| Current mycophenolate, n/N () | 9/107 (8.4) |
| Current rituximab, n/N () | 1/107 (0.9) |
| Current calcium supplementation, n/N () | 56/107 (52.3) |
| Current vitamin D supplementation, n/N () | 61/107 (57.0) |
| SLE disease activity index 2K (SLEDAI 2K), median (range) | 4 (0-12) |
| Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI), median (range) | 1 (0-6) |
|
